Cell and gene therapies require extensive safety testing all the way from raw materials to commercial lot release. The inherent variability of biologics, small sample sizes and the need for rapid turn- around times all add to the complexity of the testing environment. Learn more about our cell and gene therapy testing offerings.
Adenoassociated virus (AAV) is often the vector of choice for gene therapies due to their low immunogenicity, ability to promote long-term gene expression, and capsid tropism-dependent tissue specificity. Representing around 37% of the current advanced therapies market, there is an ongoing demand for robust quality lot release programs capable of supporting the large patient cohorts …Read More >
New state-of-the-art advanced therapies testing laboratories provide additional capacity for the growing cell and gene therapy industry. WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, has opened its advanced therapies testing facility at 400 Rouse Boulevard in Philadelphia’s Navy Yard. The new facility, which includes 140,000 square feet laboratories, will further …Read More >
In recent years, the demand for cell and gene therapy has increased substantially. The success in gene and cell therapy has also increased demand for plasmid DNA. In supplying the industry with high-quality plasmid DNA, key prominent market challenges are capacity availability, accelerated turnaround time (TAT), and affordability. In this presentation, WuXi Advanced Therapies will …Read More >
WuXi Advanced Therapies has added Mycoplasma Real-Time PCR Detection (MycoSEQ™) to our menu of innovative solutions! This assay method can be used for lot release by drugmakers of biotherapeutics, cell therapy products, biologics, and vaccines to detects more than 90 mycoplasma species with high specificity and no cross-reactivity to closely-related bacterial species rapidly and reliably. …Read More >